• Home
  • About OptiScan
    • About OptiScan
    • Leadership
    • Board of Directors
  • Clinical Results
    • Clinical Results
    • Clinical Benefits
  • Technology/Products
    • Technology/Products
    • OptiScanner 5000
    • FAQs
  • Careers
  • News and Events
  • Contact Us
  • Home
  • About OptiScan
    • About OptiScan
    • Leadership
    • Board of Directors
  • Clinical Results
    • Clinical Results
    • Clinical Benefits
  • Technology/Products
    • Technology/Products
    • OptiScanner 5000
    • FAQs
  • Careers
  • News and Events
  • Contact Us

Archives

Tag Archives for: "glucose monitoring"
Home /
By Cindy Cullen
In Misc., Press Releases
Posted October 18, 2017

OptiScan Biomedical’s OptiScanner® 5000 Receives 510(k) Clearance from US Food and Drug Administration for the First Inline Continuous Glucose Monitor in the SICU

OptiScan Biomedical’s OptiScanner® 5000 Receives 510(k) Clearance from US Food and Drug Administration for the First Inline Continuous Glucose Monitor in the SICU First-of-its-Kind Automated, [...]

Read More
By Lynn Hood
In Press Releases
Posted January 26, 2017

OptiScan Biomedical Receives CE Mark for OptiScanner® 6000 Automated Device for Monitoring Multiple Key Analytes in ICU Patients

Company Secures EU Certification for World’s First Non-Calibrated Automated System for Continuous Monitoring of Multiple Analytes in Critically Ill Patients   San Francisco, CA, January 9, [...]

Read More
By Cindy Cullen
In Press Releases
Posted April 28, 2014

OptiScan Biomedical Enrolls First Patient in Pivotal U.S. Clinical Study of OptiScanner® 5000

Pivotal Trial to Build on Previous Positive Studies; Aims to Further Demonstrate Paradigm-Shifting Potential of Automated, Bedside Glucose Monitoring System in the ICU —   HAYWARD, Calif., [...]

Read More
By Cindy Cullen
In Press Releases
Posted March 21, 2013

33rd Annual ISICEM Conference Symposium Features Breakthrough Clinical Results Supporting OptiScanner™ from OptiScan Biomedical

Industry Thought-Leaders Highlight Paradigm-Shifting Potential of Automated, Bedside Glucose Monitoring System for Critically Ill Patients   BRUSSELS, Belgium, March 21, 2013 – OptiScan [...]

Read More
By Cindy Cullen
In Press Releases
Posted March 21, 2012

OptiScan Biomedical Presents Study Results Demonstrating OptiScanner’s Excellent Glucose Monitoring Accuracy in Critically Ill ICU Patients

All Measurement Readings Demonstrate Sufficient Accuracy to Guide Clinical Treatment Decisions; Results Achieved in Most Severely Ill Patients —   BRUSSELS, March 21, 2012 – OptiScan [...]

Read More
RECENT RELEASES
  • OptiScan Biomedical Receives CE Mark for OptiScanner ® 7000 for Automated Multivariate Monitoring of Metabolic and Hemodynamic Status of Patients in the Intensive Care Unit
    May 12, 2020
  • OptiScan Biomedical Announces Peer-Reviewed Publications Highlighting First-of-its-Kind Continuous Monitoring Platform for Intensive Care Units
    December 7, 2019
  • OptiScan Biomedical Completes $20 Million Series E Financing
    March 20, 2019





Copyright ©2018 OptiScan. All Rights Reserved.